About SINTX
SINTX is a company based in Salt Lake City (United States) founded in 1996. SINTX has raised $122.4 million across 17 funding rounds from investors including NIH, HHS and Oxford Finance. The company has 20 employees as of December 31, 2024. SINTX has completed 1 acquisition, including Technology Assessment & Transfer. SINTX offers products and services including Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing. SINTX operates in a competitive market with competitors including RevBio, ParaGen Technologies, Avisi Technologies, Helicoid Industries and Dianomi Therapeutics, among others.
- Headquarter Salt Lake City, United States
- Employees 20 as on 31 Dec, 2024
- Stage Public
-
Sectors
Chemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sintx Technologies, Inc.
-
Annual Revenue
$2.89 M (USD)9.9as on Dec 31, 2024
-
Net Profit
-$11.02 M (USD)-33.48as on Dec 31, 2024
-
EBITDA
-$7.65 M (USD)34.59as on Dec 31, 2024
-
Total Equity Funding
$122.4 M (USD)
in 17 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Feb 20, 2025
-
Investors
NIH
& 4 more
-
Employee Count
20
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of SINTX
SINTX is a publicly listed company on the NASDAQ with ticker symbol SINT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of SINTX
SINTX offers a comprehensive portfolio of products and services, including Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing.
Hard, corrosion-resistant ceramic for industrial and high-temperature applications.
Ceramic with antibacterial properties for medical implants and devices.
Service for transforming concepts into printed parts using advanced ceramics.
Funding Insights of SINTX
SINTX has successfully raised a total of $122.4M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SINTX
SINTX has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for SINTX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SINTX
SINTX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Technology Assessment & Transfer.
Investment portfolio details for SINTX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of metal services
|
Locked | Locked | 1983 | Locked |
Complete acquisition details for SINTX
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SINTX
Detailed financials for SINTX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sintx Comparisons
Peer comparison for SINTX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SINTX
SINTX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RevBio, ParaGen Technologies, Avisi Technologies, Helicoid Industries and Dianomi Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Synthetic adhesives for bone and dental repair are developed.
|
|
| Locked | Locked | Locked |
Tissue engineering technologies are developed with synthetic nanofiber scaffolds.
|
|
| Locked | Locked | Locked |
Nano-materials for glaucoma treatment implants are developed.
|
|
| Locked | Locked | Locked |
Composite materials and components are produced using helicoid structures.
|
|
| Locked | Locked | Locked |
Therapies for inflammatory diseases are developed via MCM technology.
|
Detailed competitors of SINTX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sintx
Complete news archive for SINTX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SINTX
SINTX was founded in 1996 and raised its 1st funding round 7 years after it was founded.
SINTX is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
B. Sonny Bal is the current CEO of SINTX.
SINTX is a funded company, having raised a total of $122.4M across 17 funding rounds to date.
As of Dec 31, 2024, the latest employee count at SINTX is 20.
Annual revenue of SINTX is $2.89M as on Dec 31, 2024.
SINTX was founded in 1996 and is based in Salt Lake City, United States. Operations center on the medical devices sector, where interbody fusion devices are produced from medical-grade silicon nitride. Bone growth is facilitated by a nano surface texture, and the materials strength exceeds that of bone. Imaging capabilities and antibacterial properties are incorporated to address clinical requirements in spinal applications.
SINTX's top competitors include RevBio, Avisi Technologies and ParaGen Technologies.
SINTX offers Silicon Nitride Industrial (STX-100), Silicon Nitride Biomedical (FleX-SN), and Composite 3D Printing.
Yes, SINTX is publicly traded on NASDAQ under the ticker symbol SINT.
SINTX has made 1 acquisition, including Technology Assessment & Transfer.
SINTX has 5 investors. Key investors include NIH, HHS, Oxford Finance, Zions Bank, and Evermore Investments.
The ticker symbol of SINTX is SINT on NASDAQ.